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Abstract
Tyrosyl-DNA phosphodiesterase I (TDP1), like most DNA repair associated proteins, is not 
essential for cell viability. However, dysfunctioning TDP1 or ATM (ataxia telangiectasia mutated) 
results in autosomal recessive neuropathology with similar phenotypes, including cerebellar 
atrophy. Dual inactivation of TDP1 and ATM causes synthetic lethality. A TDP1H493R catalytic 
mutant is associated with spinocerebellar ataxia with axonal neuropathy (SCAN1), and stabilizes 
the TDP1 catalytic obligatory enzyme-DNA covalent complex. The ATM kinase activates proteins 
early on in response to DNA damage. Tdp1−/− and Atm−/− mice exhibit accumulation of DNA 
topoisomerase I-DNA covalent complexes (TOPO1-cc) explicitly in neuronal tissue during 
development. TDP1 resolves 3’- and 5’-DNA adducts including trapped TOPO1-cc and TOPO1 
protease resistant peptide-DNA complex. ATM appears to regulate the response to TOPO1-cc via 
a noncanonical function by regulating SUMO/ubiquitin-mediated TOPO1 degradation. In 
conclusion, TDP1 and ATM are critical factors for neuronal cell viability via two independent but 
cooperative pathways.
Tyrosyl-DNA phosphodiesterase I (TDP1), a eukaryotic DNA repair enzyme that belongs to 
the phospholipase D super family1-3, is ubiquitously expressed in most if not all human and 
mouse tissue, from neurons to peripheral skeletal cells4. In the cell, TDP1 is detected in the 
nuclear-, cytosolic- and mitochondrial-compartments4,5. TDP1 is able to resolve a wide 
variety of phospho-adducts from the 3’ and 5’ ends of nicked DNA strands. Tdp1 substrates 
vary from small adducts, such as oxidative DNA damage and chain terminating nucleotides, 
to large adducts including potentially lethal protein-DNA covalent complexes or the 
protease-resistant peptides that are still covalently linked to the DNA after degradation6,7. 
Protein-DNA adducts include DNA topoisomerases (TOPOs) covalently linked to the DNA 
via a 3’phospho-tyrosyl or 5’phospho-tyrosyl linkage, representing a TOPO1-DNA 
(TOPO1-cc) or TOPO2-/TOPO3-DNA covalent complex, respectively8-10. In addition, 
TDP1 is able to hydrolyze a 3’phospho-histidyl linkage or TDP1 covalently bound to the 
DNA (TDP1-cc)11-13. Note: higher eukaryotic cells contain an additional enzyme called 
TDP2/TTRAP that resolves the 5’phospho-tyrosyl linkages more efficiently then TDP114-17. 
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However, this enzyme is absent in yeast cells in which TDP1 resolved both 3’ and 
5’phospho-tyrosyl linkages18.
To resolve this eclectic array of phospho-adducts, TDP1 utilizes the coordinated action of 
two catalytic histidines (Figure 1). In the case of hydrolyzing a 3’phospho-tyrosyl linkage, 
the N-terminally located histidine functions as a nucleophile (Hisnuc; His263 in human 
(h)Tdp1 and His182 in yeast (y)Tdp1) to attack the 3’phospho-tyrosyl linkage to form a 
3’phospho-hystidyl bond. The C-terminally located histidine acts as a general acid/base 
(Hisgab; His493 in hTdp1 and His432 in yTdp1) that activates a water molecule to hydrolyze 
the Tdp1-DNA linkage formed in the first step, resulting in separation of Tdp1 from the 
DNA1,2,11,19.
A substitution of the hTdp1Hisgab to Arginine (hTdp1H493R) has been identified as the 
molecular basis for the rare autosomal recessive neurodegenerative disease Spinocerebellar 
Ataxia with Axonal Neuropathy or SCAN113. SCAN1 symptoms are similar to Ataxia 
Telangiectasia (A-T) and Ataxia with Oculomoter Apraxia (AOA1). A-T results from 
defects in the serine/threonine protein kinase, DNA damage response regulator ATM (ataxia 
telangiectasia mutated20, and AOA1 is caused by a defect in the DNA repair enzyme 
aprataxin (APTX)21, respectively13,22. ATM is activated in response to the detection of 
double-strand breaks via the Mre11-Rad50-Nsb1 (MRN) complex to phosphorylate a 
plethora of downstream proteins, including H2AX and p5323,24. On the other hand, APTX is 
an adenyl-hydrolase that resolves 5’adenylated-DNA (5’AMP-DNA) adducts as a result of 
abortive DNA ligase activity21,25. The importance of DNA “end-processing” enzyme 
activities became even more evident with the observation that mutations in the kinase 
domain of polynucleotide kinase phosphatase (PNKP) are associated with AOA4, while 
other substitution in PNKP are detected in patients with microcephaly with seizures (MCSZ) 
(26-28). Moreover, loss of TDP2 activity is associated with autosome recessive 
spinocerebellar ataxia-23 or SCAR-2329,30.
SCAN1 patients demonstrate a progressive cerebellar atrophy that results in ataxia 
symptoms during late childhood (13-15 years). Intriguingly, this atrophy only seems to 
affect the cerebellar neurons within the vermis region of the cerebellum13,22. Moreover, 
these patients do not show an increase in cancer predisposition, immunodeficiencies, or 
cardiomyopathy. Takashima and colleagues originally proposed that the H493R substitution 
would inactivate the enzyme13; however, subsequent biochemical studies revealed a 
decreased dissociation rate resulting in an increased level of TDP1SCAN1-cc (Figure 1)31-33. 
Moreover, the only available resolved crystal structure of a Tdp1HisgabArg mutant enzyme 
is the yeast analogous substitution (yTdp1H432R)32. The yTdp1H432R crystal structure 
demonstrated that the arginine side chain reduces the depth of the TDP1 catalytic pocket, 
potentially obstructing a water molecule to enter the pocket at the correct position32. On the 
other hand, arginine is also a weaker general acid/base than histidine, which affects the 
activation rate of the water molecule that facilitates dissociation of Tdp1 from the DNA. 
Additionally, the arginine guanidinium moiety changes the electrostatic charge distribution 
within the catalytic pocket to highly positive32. All these factors contribute to the reduced 
dissociation rate of TDP1HisgabArg from the DNA. The biochemical/biophysical 
characteristics of the HisgabArg substitution as well as the mild cellular toxicity induced by 
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expression of this TDP1HgabR-mutant are conserved between yeast and human 
TDP111,31-33. Moreover, examination of additional substitutions of the Hisgab/432 in yTdp1 
showed that a His432Lys substitution resulted in a minor (~10-fold) decrease in catalytic 
activity with no detectable toxicity32. Conversely, expression of His432 substitution with 
residues that contain a smaller polar or aliphatic side chain such as Asn, Glu, Ser, Thr, Leu, 
Val and Ala, displays an acute toxicity, albeit recessive to wild type Tdp1. These 
observations also revealed that the SCAN1 mutation (HisgabArg) among the toxic Hisgab 
mutants exhibits only a mildly toxic phenotype. Similar to the SCAN1 mutant, the toxicity 
induced by expression of the HisgabAsn mutant is correlated with increased cellular levels of 
enzyme-DNA intermediates and a reduction in catalytic activity in both yeast and human 
TDP111,31-34 [Cuya, van Waardenburg manuscript under revision Oncotarget]. It is therefore 
intriguing that more TDP1 single nucleotide polymorphisms are not identified and 
associated with neuronal syndromes or other diseases associated with genome instability 
etiology. Although substitution of either catalytic histidine results in a gain of function 
(toxicity and reduced activity)11,32,34, two questions remain open: How does the Tdp1H493R 
mutant enzyme cause the SCAN1 pathology? and Why are (cerebellar) neurons so sensitive 
to this toxic Tdp1 mutant?
Tdp1, like most DNA repair proteins/enzymes, is not essential for eukaryotic cell viability. 
This is generally due to the existence of redundant DNA repair processes that are able to 
resolve protein-DNA adducts. However, some human carcinomas developed a dependency 
on/or addiction of Tdp1 expression35,36. Currently, no mouse model for SCAN1 that 
expresses the HisgabArg substitution has been generated. However, three different groups 
generated a Tdp1 knockout mouse37-39. Interestingly, Tdp1−/− mice do not develop any 
ataxia or neuropathy symptoms related with SCAN1 or other behavioral phenotypes, and 
their electrophysiology is comparable to their wild-type37-39. However, these Tdp1−/− mice 
do develop age-dependent progressive cerebellar atrophy, and display one of the non-
neuronal related SCAN1 symptoms, hypoalbuminemia13,22,39. The Tdp1−/− mice also 
exhibit an expected hypersensitivity to camptothecin (CPT) or topotecan treatment (a FDA 
approved camptothecin chemotherapeutic) that was evident in proliferating intestinal cells 
and hematopoietic cells37-39. Moreover, Tdp1−/− fibroblast extracts show a deficiency in 
their ability to process 3’phospho-glycolate adducts within double-stranded DNA breaks but 
not single-strand breaks, and these cells show an increased bleomycin sensitivity37,38.
On the other hand, Mckinnon and coworkers reported that TDP1 and ATM are critical 
during the development of neuronal cells to control TOPO1 induced DNA damage (40). 
Mice can survive the individual inactivation of ATM or TDP1; however, dual inactivation 
causes synthetic lethality. The Atm−/−,Tdp1−/− combination showed to be embryonically 
lethal between E13.5 and E16.5, a period in which the TOPO1-cc levels are at their 
maximum40. TOPO1 can be trapped onto the DNA by endogenous DNA lesions, such as 
abasic sites and single-strand nicks which can occur due to oxidative damage41,42. Indeed, 
Tdp1−/− and Atm−/− mice show elevated levels of TOPO1-cc in cortical/cerebella tissue 
during embryonic development up to one year after birth, while control cells or other tissue 
in the knockout mice show no or minor levels of TOPO1-cc40. This suggests that during 
development TOPO1-cc lesions accumulated specifically in the neuronal tissue and that for a 
normal homeostasis ATM and TDP1 regulation of processing stalled TOPO1-cc is critical.
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The accumulation of TOPO1-cc and single-strand DNA breaks in the ATM−/− and Tdp1−/− 
quiescent primary astrocytes is even more pronounced after camptothecin (CPT), ionizing 
radiation, or hydrogen peroxide treatment. ATM's response to TOPO1-cc in neuronal cells is 
independent of its kinase activity or other canonical functions. Inactivation of MRE11, 
DNA-PKcs, or LIG4 in combination with Tdp1−/− exhibits a normal Mendelian offspring 
distribution without an obvious phenotype40. However, inactivation of XRCC1 [the scaffold 
protein within the base excision repair (BER) pathway, which partners include TDP143] 
showed elevated levels of TOPO1-cc similar to Atm inactivation that are lower than Tdp1 
inactivation. Inactivation of Xrcc1 did not reduce the protein levels of TDP1 or other BER 
affiliated proteins, while the combination of Atm and Xrcc1 inactivation accumulates 
TOPO1-cc levels similar to Tdp1 inactivation. In an effort to identify the non-canonical 
function of ATM, Katyal et al observed that ATM is able to regulate post-translational 
modification (PTM) of TOPO1 by SUMOylation of TOPO1 and ubiquitination via a yet 
unknown pathway40. These ATM stimulated PTMs in response to CPT treatment, stimulate 
proteasome-mediated degradation of TOPO1 which was prevented by proteasome inhibitor 
MG132. The response was lost in A-T cells but still active after treatment with an ATM 
inhibitor, suggesting that ATM kinase activity is not involved in this response.
In conclusion, both ATM and TDP1 play a critical protective role during neuronal 
development to prevent accumulation of TOPO1-cc (Figure 2). ATM neuronal cells via a 
novel non-canonical activity, which does not require ATM kinase function. ATM regulates 
posttranscriptional modification of TOPO1 and potentially TOPO1-cc by stimulating 
SUMOylation, followed by ubiquitination that promotes proteasome-mediated TOPO1 
degradation (Figure 2). Although no SUMO E3-ligases or ubiquitin E2-conjugation/E3-
ligase complexes have been identified, in yeast two potential complexes were identified. 
First is the SUMO ligase Pli1 mediates SUMO modification of TOPO1 while the SUMO-
targeted ubiquitin ligase Slx8 was shown to mediate ubiquitin modification44. The second 
complex is the DNA-, SUMO- and ubiquitin-dependent metalloprotease complex WSS1/
CDC48/DOA1 might be responsible for the degradation of modified TOPO1-cc45. The 
WSS1 human analog is Spartan/DVC1 protein. TDP1, on the other hand, hydrolyzes the 
3’phospho-tyrosyl linkage that covalently attaches full length TOPO1 with the 3’phosphoryl 
end of a DNA strand or the protease resistant TOPO1-peptide1,11. Thus, TDP1 plays a 
critical role in removal of a protein/peptide-DNA adduct during neuronal development 
(Figure 2). These studies suggest a potential molecular basis for the etiology of SCAN1; not 
only TOPO1-cc are accumulating during embryonic development but they are replaced by 
TDP1H493R-cc, which together maximizes the ability of ATM and the other repair pathways 
to maintain cell viability, resulting in a slow but progressive cerebellar atrophy (Figure 2). 
Moreover, the work of McKinnon and coworkers40 gave the first clue, specific accumulation 
of TOPO1-cc in the neuronal cells, of why the cerebellar is specifically affected and not 
other tissues.
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Figure 1. 
The TDP1 catalytic pocket and mechanism is conserved from yeast to human. (a) Overlay of 
the crystal structure catalytic pockets of yeast and human Tdp1 showing the two catalytic 
HxKxnN-motifs; H263,K265,N283 N-terminal motif and H493,K495,N516 C-terminal 
motif in human TDP1. H182,K185,N203 N-terminal motif and H432,K435,N434 C-
terminal motif in yeast TDP1. Residues H263 in human TDP1 and H182 of yeast TDP1 
represent the nucleophilic histidine (Hisnuc), while H493 of human TDP1 and H432 in yeast 
TDP1 represent the general acid/base histidine (Hisgab). [human TDP1; PDB # 1NOP46 and 
yeast TDP1; PDB# 1Q3211]. (b) Tdp1 catalytic of DNA topoisomerase I-DNA covalent 
complexes (TOPO1-cc); Tdp1 resolves the 3’phospho-tyrosyl linkage (Y) via nucleophilic 
attack of the Hisnuc (Hn), that releases TOPO1. This step generates the obligatory TDP1-
DNA intermediate via 3’phospho-amide linkage. Water is activated by Hisgab (Hg) to 
hydrolyze the TDP1-DNA linkage allowing TDP1 to dissociate from the DNA. The exciting 
single-strand nick requires further processing by polynucleotide kinase-phosphatase (PNKP) 
prior to DNA ligation.
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Figure 2. 
TOPO1-cc processing by TDP1 and ATM independent pathways in neuronal cells. The 
removal of accumulated TOPO1-cc in neuronal cells during development by noncanonical 
ATM-regulated SUMOylated (yellow hexagon) followed by ubiquitination (red star) of 
TOPO1 that results in TOPO1 degradation potentially proteasome-mediated40 or by SUMO 
stimulated selective ESCRT vesicle-trafficking mediated autophagy47. The protease-resistant 
covalently linked TOPO1-peptide and, independent of ATM, TOPO1-cc can be directly 
removed by TDP1-mediated hydrolysis. In SCAN1 patients, the TDP1H493R mutant 
enzyme will be able to hydrolyze both TOPO1-cc and the TOPO1-peptide fragment from 
the DNA but will form a stable TDP1H493R-cc11,13,31-33. The accumulated TDP1H493R-cc 
together with the TOPO1-cc or TOPO1-peptite-DNA complex will maximally challenge the 
ATM and other DNA repair pathways, resulting in slow progressive cerebellar atrophy.
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